Relevance of molecular characterization of circulating tumor cells in breast cancer in the era of targeted therapies

Expert Review of Molecular Diagnostics

Volumn 13, Issue 3, 2013, Pages 295-307

  Nadal, Rosa ^a,b   Lorente, José Antonio ^b   Rosell, Rafael ^c,d   Serrano, María Jose ^b  

^a Hospital de Niños de Barcelona   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

biomarkers; breast cancer; circulating tumor cells; CTC detection methods; epithelial mesenchymal transition; liquid biopsy; molecular characterization; stem cell phenotype; targeted therapies

Indexed keywords

AFATINIB; AFLIBERCEPT; CARCINOEMBRYONIC ANTIGEN; CD45 ANTIGEN; CYTOKERATIN 18; CYTOKERATIN 19; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; EVEROLIMUS; INIPARIB; LAPATINIB; MAMMAGLOBIN; MAYTANSINE; MUCIN 1; NERATINIB; OLAPARIB; PAZOPANIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; SUNITINIB; TRASTUZUMAB;

ANALYTICAL EQUIPMENT; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CELL ADHESION; CELL ASSAY; CIRCULATING TUMOR CELL; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENOTYPE; HUMAN; METASTASIS; MICROMETASTASIS; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL;

ANIMALS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84876142901     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.13.7     Document Type: Review

References (104)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10-29 (2012
2. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat. Rev. Cancer 4(6), 448-456 (2004
3. Husemann Y, Geigl JB, Schubert F et al. Systemic spread is an early step in breast cancer. Cancer Cell 13(1), 58-68 (2008
4. Nagrath S, Sequist LV, Maheswaran S et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450(7173), 1235-1239 (2007
5. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351(8), 781-791 (2004
6. Cristofanilli M, Hayes DF, Budd GT et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 23(7), 1420-1430 (2005
7. Pierga JY, Bidard FC, Mathiot C et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a Phase II randomized trial. Clin. Cancer Res. 14(21), 7004-7010 (2008
8. Rack B, Schindlbeck C, Schneeweiss A et al: Prognostic relevance of circulating tumor cells in the peripheral blood of primary breast cancer patients. Presented at: 33rd San Antonio Breast Cancer Symposium. TX, USA, 8-12 December 2010 (Abstract 503
9. Bidard FC, Mathiot C, Delaloge S et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann. Oncol. 21(4), 729-733 (2010
10. Lucci A, Hall CS, Lodhi AK et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 13(7), 688-695 (2012
11. Zhang L, Riethdorf S, Wu G et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin. Cancer Res. 18(20), 5701-5710 (2012
12. Fehm T, Muller V, Alix-Panabières C, Pantel K. Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance. Breast Cancer Res. 10(Suppl. 1), S1 (2008
13. Pinzani P, Salvadori B, Simi L et al. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. Hum. Pathol. 37(6), 711-718 (2006
14. Zach O, Lutz D. Tumor cell detection in peripheral blood and bone marrow. Curr. Opin. Oncol. 18(1), 48-56 (2006
15. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 253(2), 180-204 (2007
16. Wong NS, Kahn HJ, Zhang L et al. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients. Breast Cancer Res. Treat. 99(1), 63-69 (2006
17. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and nononcogene addiction. Cell 136(5), 823-837 (2009
18. Meng S, Tripathy D, Shete S et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc. Natl Acad. Sci. USA 101(25), 9393-9398 (2004
19. Nadal R, Fernandez A, Sanchez-Rovira P et al. Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res. 14(3), R71 (2012
20. Riethdorf S, Muller V, Zhang L et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin. Cancer Res. 16(9), 2634-2645 (2010
21. Fehm T, Hoffmann O, Aktas B et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 11(4), R59 (2009
22. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2- positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005
23. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358(11), 1160-1174 (2008
24. Antonescu CR. Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Mod. Pathol. 21(Suppl. 2), S31-S36 (2008
25. Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359(4), 366-377 (2008
26. Georgoulias V, Bozionelou V, Agelaki S et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapyresistant CK-19 mRNA-positive circulating tumor cells: results of a randomized Phase II study. Ann. Oncol. 23(7), 1744-1750 (2012
27. Nunes RA, Li X, Kang SP et al. Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. Int. J. Biol. Markers 24(1), 1-10 (2009
28. Klein CA. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 9(4), 302-312 (2009
29. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 17(5), 548-558 (2005
30. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 331(6024), 1559-1564 (2011
31. Naume B, Zhao X, Synnestvedt M et al. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol. Oncol. 1(2), 160-171 (2007
32. Bonnomet A, Brysse A, Tachsidis A et al. Epithelial-to-mesenchymal transitions and circulating tumor cells. J. Mammary Gland Biol. Neoplasia 15(2), 261-273 (2010
33. Mani SA, Guo W, Liao MJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4), 704-715 (2008
34. Meng S, Tripathy D, Frenkel EP et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 10(24), 8152-8162 (2004
35. Retsky MW, Demicheli R, Hrushesky WJ, Baum M, Gukas ID. Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. APMIS 116(7-8), 730-741 (2008
36. Serrano MJ, Nadal R, Lorente JA et al. Circulating cancer cells in division in an early breast cancer patient. Ann. Oncol. 22(9), 2150-2151 (2011
37. Kim MY, Oskarsson T, Acharyya S et al. Tumor self-seeding by circulating cancer cells. Cell 139(7), 1315-1326 (2009
38. Smith BM, Slade MJ, English J et al. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J. Clin. Oncol. 18(7), 1432-1439 (2000
39. Braun S, Pantel K, Muller P et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N. Engl. J. Med. 342(8), 525-533 (2000
40. Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10(20), 6897-6904 (2004
41. Riethdorf S, Fritsche H, Muller V et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin. Cancer Res. 13(3), 920-928 (2007
42. Berois N, Varangot M, Aizen B et al. Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer. Comparison of CK19, MUC1 and CEA using RT-PCR. Eur. J. Cancer 36(6), 717-723 (2000
43. Benoy IH, Elst H, Philips M et al. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br. J. Cancer 94(5), 672-680 (2006
44. Muller V, Riethdorf S, Rack B et al.; on behalf of the DETECT study group. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res. 14(4), R118 (2012
45. Pachmann K, Clement JH, Schneider CP et al. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin. Chem. Lab. Med. 43(6), 617-627 (2005
46. Alix-Panabières C, Brouillet JP, Fabbro M et al. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J. Immunol. Methods 299(1-2), 177-188 (2005
47. Ignatiadis M, Xenidis N, Perraki M et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J. Clin. Oncol. 25(33), 5194-5202 (2007
48. Desitter I, Guerrouahen BS, Benali-Furet N et al. A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res. 31(2), 427-441 (2011
49. Saucedo-Zeni N, Mewes S, Niestroj R et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int. J. Oncol. doi:10.3892/ijo.2012.1557 (2012) (Epub ahead of print
50. Hayes DF, Cristofanilli M, Budd GT et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progressionfree and overall survival. Clin. Cancer Res. 12(14 Pt 1), 4218-4224 (2006
51. Budd GT, Cristofanilli M, Ellis MJ et al. Circulating tumor cells versus imaging - predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12(21), 6403-6409 (2006
52. Liu MC, Shields PG, Warren RD et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J. Clin. Oncol. 27(31), 5153-5159 (2009
53. Cristofanilli M, Broglio KR, Guarneri V et al. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin. Breast Cancer 7(6), 471-479 (2007
54. Giordano A, Giuliano M, De Laurentiis M et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann. Oncol. 23(5), 1144-1150 (2012
55. Bidard FC, Hajage D, Bachelot T et al. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. Breast Cancer Res. 14(1), R29 (2012
56. Pantel K, Alix-Panabières C, Riethdorf S. Cancer micrometastases. Nat. Rev. Clin. Oncol. 6(6), 339-351 (2009
57. Krishnamurthy S, Cristofanilli M, Singh B et al. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer 116(14), 3330-3337 (2010
58. Xenidis N, Ignatiadis M, Apostolaki S et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J. Clin. Oncol. 27(13), 2177-2184 (2009
59. Saloustros E, Perraki M, Apostolaki S et al. Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. Breast Cancer Res. 13(3), R60 (2011
60. American Joint Commission on Cancer Staging. AJJC Cancer Staging Manual. Springer, NY, USA (2010
61. Sieuwerts AM, Kraan J, Bolt J et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J. Natl Cancer Inst. 101(1), 61-66 (2009
62. Mostert B, Kraan J, Sieuwerts AM et al. CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. Cancer Lett. 319(1), 49-55 (2012
63. Effenberger KE, Borgen E, Eulenburg CZ et al. Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern. Breast Cancer Res. Treat. 125(3), 729-738 (2011
64. Joosse SA, Hannemann J, Spotter J et al. Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clin. Cancer Res. 18(4), 993-1003 (2012
65. Tsuji T, Ibaragi S, Hu GF. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res. 69(18), 7135-7139 (2009
66. Behrens J. Cadherins and catenins: role in signal transduction and tumor progression. Cancer Metastasis Rev. 18(1), 15-30 (1999
67. Mostert B, Kraan J, Bolt-de Vries J et al. Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res. Treat. 127(1), 33-41 (2011
68. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 11(4), R46 (2009
69. Mego M, Mani SA, Lee BN et al. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: the effect of neoadjuvant therapy. Int. J. Cancer 130(4), 808-816 (2012
70. Raimondi C, Gradilone A, Naso G et al. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res. Treat. 130(2), 449-455 (2011
71. Gradilone A, Raimondi C, Nicolazzo C et al. Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. J. Cell. Mol. Med. 15(5), 1066-1070 (2011
72. Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res. 14(1), R15 (2012
73. Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 13(3), R59 (2011
74. Giordano A, Gao H, Anfossi S et al. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol. Cancer Ther. 11(11), 2526-2534 (2012
75. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100(7), 3983-3988 (2003
76. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5), 555-567 (2007
77. Theodoropoulos PA, Polioudaki H, Agelaki S et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 288(1), 99-106 (2010
78. Kallergi G, Agelaki S, Kalykaki A, Stournaras C, Mavroudis D, Georgoulias V. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res. 10(5), R80 (2008
79. Korkaya H, Paulson A, Charafe-Jauffret E et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 7(6), e1000121 (2009
80. Gradilone A, Naso G, Raimondi C et al. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Ann. Oncol. 22(1), 86-92 (2011
81. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 22(3), 373-388 (2012
82. Oakman C, Santarpia L, Di Leo A. Breast cancer assessment tools and optimizing adjuvant therapy. Nat. Rev. Clin. Oncol. 7(12), 725-732 (2010
83. Ibrahim T, Farolfi A, Scarpi E et al. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact. Oncology 84(3), 150-157 (2013
84. Pestrin M, Bessi S, Galardi F et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res. Treat. 118(3), 523-530 (2009
85. Munzone E, Nole F, Goldhirsch A et al. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin. Breast Cancer 10(5), 392-397 (2010
86. Wulfing P, Borchard J, Buerger H et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin. Cancer Res. 12(6), 1715-1720 (2006
87. Fehm T, Muller V, Aktas B et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res. Treat. 124(2), 403-412 (2010
88. Flores LM, Kindelberger DW, Ligon AH et al. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br. J. Cancer 102(10), 1495-1502 (2010
89. Hayashi N, Nakamura S, Tokuda Y et al. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int. J. Clin. Oncol. 17(2), 96-104 (2012
90. Apostolaki S, Perraki M, Kallergi G et al. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. Breast Cancer Res. Treat. 117(3), 525-534 (2009
91. Niikura N, Liu J, Hayashi N et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J. Clin. Oncol. 30(6), 593-599 (2012
92. Solomayer EF, Becker S, Pergola-Becker G et al. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res. Treat. 98(2), 179-184 (2006
93. Ignatiadis M, Rothe F, Chaboteaux C et al. HER2-positive circulating tumor cells in breast cancer. PLoS ONE 6(1), e15624 (2011
94. Punnoose EA, Atwal SK, Spoerke JM et al. Molecular biomarker analyses using circulating tumor cells. PLoS ONE 5(9), e12517 (2010
95. Bozionellou V, Mavroudis D, Perraki M et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin. Cancer Res. 10(24), 8185-8194 (2004
96. Banys M, Krawczyk N, Becker S et al. The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Breast Cancer Res. Treat. 132(1), 121-129 (2012
97. Aktas B, Muller V, Tewes M et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol. Oncol. 122(2), 356-360 (2011
98. Tewes M, Aktas B, Welt A et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res. Treat. 115(3), 581-590 (2009
99. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol. 21(11), 2101-2109 (2003
100. Goswami S, Sahai E, Wyckoff JB et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 65(12), 5278-5283 (2005
101. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2- positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006
102. Liu Z, Fusi A, Schmittel A, Tinhofer I, Schneider A, Keilholz U. Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine. Cancer Biol. Ther. 10(9), 860-864 (2010
103. Gaforio JJ, Serrano MJ, Sanchez-Rovira P et al. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int. J. Cancer 107(6), 984-990 (2003
104. Liu Z, Fusi A, Klopocki E et al. Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients. J. Transl. Med. 9, 70 (2011